Which has better valuation & earnings, IMUX or VERU?

Veru has higher revenue and earnings than Immunic. Veru is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Immunic N/A N/A -$97.17M -$4.38 N/A Veru $16.89M 2.56 -$22.73M -$0.69 N/A

Is IMUX or VERU more profitable?

Veru's return on equity of -47.58% beat Immunic's return on equity. Company Net Margins Return on Equity Return on Assets Immunic N/A -157.89% -107.88% Veru N/A -47.58% -35.83%

Does the media refer more to IMUX or VERU?

In the previous week, Immunic and Immunic both had 2 articles in the media. Immunic's average media sentiment score of 1.82 beat Veru's score of 0.72 indicating that Immunic is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunic 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Veru 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate MENS or VERU?

Veru has a consensus price target of $24.50, indicating a potential upside of 864.57%. Given Veru's stronger consensus rating and higher probable upside, analysts plainly believe Veru is more favorable than Jyong Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Veru 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Which has stronger valuation & earnings, MENS or VERU?

Jyong Biotech has higher earnings, but lower revenue than Veru. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jyong Biotech N/A N/A -$4.67M N/A N/A Veru $16.89M 2.56 -$22.73M -$0.69 N/A

Is MENS or VERU more profitable?

Jyong Biotech's return on equity of 0.00% beat Veru's return on equity. Company Net Margins Return on Equity Return on Assets Jyong Biotech N/A N/A N/A Veru N/A -47.58% -35.83%

Is VERU or NRXP more profitable?

Veru has a net margin of 0.00% compared to NRx Pharmaceuticals' net margin of -691.81%. NRx Pharmaceuticals' return on equity of 0.00% beat Veru's return on equity. Company Net Margins Return on Equity Return on Assets Veru N/A -47.58% -35.83% NRx Pharmaceuticals -691.81% N/A -63.92%

Does the media refer more to VERU or NRXP?

In the previous week, Veru and Veru both had 2 articles in the media. NRx Pharmaceuticals' average media sentiment score of 0.89 beat Veru's score of 0.72 indicating that NRx Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veru 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive NRx Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is VERU or UNCY more profitable?

Veru's return on equity of -47.58% beat Unicycive Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Veru N/A -47.58% -35.83% Unicycive Therapeutics N/A -91.50% -61.47%

Does the media prefer VERU or UNCY?

In the previous week, Unicycive Therapeutics had 11 more articles in the media than Veru. MarketBeat recorded 13 mentions for Unicycive Therapeutics and 2 mentions for Veru. Veru's average media sentiment score of 0.72 beat Unicycive Therapeutics' score of 0.14 indicating that Veru is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veru 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Unicycive Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 11 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Veru (VERU) Competitors

$2.54 +0.03 (+1.20%)

Closing price 09/25/2026 04:00 PM Eastern

Extended Trading

$2.52 -0.02 (-0.59%)

As of 09/25/2026 07:46 PM Eastern

Compare

VERU vs. LFCR, IMUX, MENS, NRXP, and UNCY

Should you buy Veru stock or one of its competitors? Veru's main competitors and comparable companies include Lifecore Biomedical (LFCR), Immunic (IMUX), Jyong Biotech (MENS), NRx Pharmaceuticals (NRXP), and Unicycive Therapeutics (UNCY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Veru compare to Lifecore Biomedical?

Veru (NASDAQ:VERU) and Lifecore Biomedical (NASDAQ:LFCR) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

47.2% of Veru shares are held by institutional investors. Comparatively, 83.4% of Lifecore Biomedical shares are held by institutional investors. 14.2% of Veru shares are held by company insiders. Comparatively, 32.7% of Lifecore Biomedical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Veru has a net margin of 0.00% compared to Lifecore Biomedical's net margin of -29.93%. Lifecore Biomedical's return on equity of 0.00% beat Veru's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veru	N/A	-47.58%	-35.83%
Lifecore Biomedical	-29.93%	N/A	-16.16%

Veru currently has a consensus target price of $24.50, indicating a potential upside of 864.57%. Lifecore Biomedical has a consensus target price of $6.50, indicating a potential upside of 54.76%. Given Veru's stronger consensus rating and higher probable upside, research analysts plainly believe Veru is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veru	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Lifecore Biomedical	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Veru had 1 more articles in the media than Lifecore Biomedical. MarketBeat recorded 2 mentions for Veru and 1 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 0.89 beat Veru's score of 0.72 indicating that Lifecore Biomedical is being referred to more favorably in the news media.

Company	Overall Sentiment
Veru	Positive
Lifecore Biomedical	Positive

Veru has a beta of -1.17, meaning that its share price is 217% less volatile than the broader market. Comparatively, Lifecore Biomedical has a beta of 1.08, meaning that its share price is 8% more volatile than the broader market.

Veru has higher earnings, but lower revenue than Lifecore Biomedical. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Veru, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veru	$16.89M	2.56	-$22.73M	-$0.69	N/A
Lifecore Biomedical	$128.87M	1.23	-$40.50M	-$1.07	N/A

Summary

Veru beats Lifecore Biomedical on 9 of the 16 factors compared between the two stocks.

How does Veru compare to Immunic?

Immunic (NASDAQ:IMUX) and Veru (NASDAQ:VERU) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.

Veru's return on equity of -47.58% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunic	N/A	-157.89%	-107.88%
Veru	N/A	-47.58%	-35.83%

Immunic has a beta of 1.41, meaning that its stock price is 41% more volatile than the broader market. Comparatively, Veru has a beta of -1.17, meaning that its stock price is 217% less volatile than the broader market.

Veru has higher revenue and earnings than Immunic. Veru is trading at a lower price-to-earnings ratio than Immunic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunic	N/A	N/A	-$97.17M	-$4.38	N/A
Veru	$16.89M	2.56	-$22.73M	-$0.69	N/A

In the previous week, Immunic and Immunic both had 2 articles in the media. Immunic's average media sentiment score of 1.82 beat Veru's score of 0.72 indicating that Immunic is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunic	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Veru	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

51.8% of Immunic shares are owned by institutional investors. Comparatively, 47.2% of Veru shares are owned by institutional investors. 5.5% of Immunic shares are owned by insiders. Comparatively, 14.2% of Veru shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Immunic presently has a consensus target price of $47.25, indicating a potential upside of 405.35%. Veru has a consensus target price of $24.50, indicating a potential upside of 864.57%. Given Veru's higher probable upside, analysts plainly believe Veru is more favorable than Immunic.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunic	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	3.00
Veru	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

Immunic and Veru tied by winning 7 of the 14 factors compared between the two stocks.

How does Veru compare to Jyong Biotech?

Jyong Biotech (NASDAQ:MENS) and Veru (NASDAQ:VERU) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, profitability, dividends, media sentiment, analyst recommendations, valuation, risk and institutional ownership.

Jyong Biotech's return on equity of 0.00% beat Veru's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jyong Biotech	N/A	N/A	N/A
Veru	N/A	-47.58%	-35.83%

Jyong Biotech has higher earnings, but lower revenue than Veru.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jyong Biotech	N/A	N/A	-$4.67M	N/A	N/A
Veru	$16.89M	2.56	-$22.73M	-$0.69	N/A

47.2% of Veru shares are owned by institutional investors. 14.2% of Veru shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Veru had 1 more articles in the media than Jyong Biotech. MarketBeat recorded 2 mentions for Veru and 1 mentions for Jyong Biotech. Jyong Biotech's average media sentiment score of 1.79 beat Veru's score of 0.72 indicating that Jyong Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Jyong Biotech	Very Positive
Veru	Positive

Veru has a consensus price target of $24.50, indicating a potential upside of 864.57%. Given Veru's stronger consensus rating and higher probable upside, analysts plainly believe Veru is more favorable than Jyong Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Veru	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Jyong Biotech has a beta of 2.24, indicating that its share price is 124% more volatile than the broader market. Comparatively, Veru has a beta of -1.17, indicating that its share price is 217% less volatile than the broader market.

Summary

Veru beats Jyong Biotech on 7 of the 12 factors compared between the two stocks.

How does Veru compare to NRx Pharmaceuticals?

Veru (NASDAQ:VERU) and NRx Pharmaceuticals (NASDAQ:NRXP) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, risk, valuation, media sentiment, analyst recommendations, institutional ownership and dividends.

Veru has a beta of -1.17, meaning that its share price is 217% less volatile than the broader market. Comparatively, NRx Pharmaceuticals has a beta of 2.19, meaning that its share price is 119% more volatile than the broader market.

Veru currently has a consensus target price of $24.50, indicating a potential upside of 864.57%. NRx Pharmaceuticals has a consensus target price of $34.50, indicating a potential upside of 1,053.85%. Given NRx Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe NRx Pharmaceuticals is more favorable than Veru.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veru	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
NRx Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43

Veru has a net margin of 0.00% compared to NRx Pharmaceuticals' net margin of -691.81%. NRx Pharmaceuticals' return on equity of 0.00% beat Veru's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veru	N/A	-47.58%	-35.83%
NRx Pharmaceuticals	-691.81%	N/A	-63.92%

Veru has higher revenue and earnings than NRx Pharmaceuticals. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Veru, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veru	$16.89M	2.56	-$22.73M	-$0.69	N/A
NRx Pharmaceuticals	$3.39M	38.14	-$28.62M	-$0.55	N/A

In the previous week, Veru and Veru both had 2 articles in the media. NRx Pharmaceuticals' average media sentiment score of 0.89 beat Veru's score of 0.72 indicating that NRx Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veru	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
NRx Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

47.2% of Veru shares are owned by institutional investors. Comparatively, 4.3% of NRx Pharmaceuticals shares are owned by institutional investors. 14.2% of Veru shares are owned by insiders. Comparatively, 6.4% of NRx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

NRx Pharmaceuticals beats Veru on 8 of the 15 factors compared between the two stocks.

How does Veru compare to Unicycive Therapeutics?

Veru (NASDAQ:VERU) and Unicycive Therapeutics (NASDAQ:UNCY) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, media sentiment, risk, earnings, institutional ownership, analyst recommendations, valuation and profitability.

47.2% of Veru shares are held by institutional investors. Comparatively, 40.4% of Unicycive Therapeutics shares are held by institutional investors. 14.2% of Veru shares are held by insiders. Comparatively, 6.0% of Unicycive Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Unicycive Therapeutics had 11 more articles in the media than Veru. MarketBeat recorded 13 mentions for Unicycive Therapeutics and 2 mentions for Veru. Veru's average media sentiment score of 0.72 beat Unicycive Therapeutics' score of 0.14 indicating that Veru is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veru	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Unicycive Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	11 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Veru has higher revenue and earnings than Unicycive Therapeutics. Veru is trading at a lower price-to-earnings ratio than Unicycive Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veru	$16.89M	2.56	-$22.73M	-$0.69	N/A
Unicycive Therapeutics	$680K	192.49	-$26.56M	-$1.75	N/A

Veru presently has a consensus price target of $24.50, suggesting a potential upside of 864.57%. Unicycive Therapeutics has a consensus price target of $18.75, suggesting a potential upside of 298.94%. Given Veru's higher probable upside, analysts clearly believe Veru is more favorable than Unicycive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veru	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Unicycive Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Veru's return on equity of -47.58% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veru	N/A	-47.58%	-35.83%
Unicycive Therapeutics	N/A	-91.50%	-61.47%

Veru has a beta of -1.17, suggesting that its share price is 217% less volatile than the broader market. Comparatively, Unicycive Therapeutics has a beta of 1.79, suggesting that its share price is 79% more volatile than the broader market.

Summary

Veru beats Unicycive Therapeutics on 9 of the 15 factors compared between the two stocks.

Get Veru News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VERU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VERU vs. The Competition

Export

Metric	Veru	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$43.31M	$12.68B	$7.33B	$13.18B
Dividend Yield	N/A	2.63%	2.52%	14.03%
P/E Ratio	-3.68	797.38	275.82	25.78
Price / Sales	2.56	787.89	603.86	72.84
Price / Cash	N/A	89.30	79.52	52.89
Price / Book	2.03	10.54	10.44	6.30
Net Income	-$22.73M	$2.85B	$3.51B	$360.35M
7 Day Performance	5.39%	-1.10%	-1.31%	-0.23%
1 Month Performance	-7.30%	-3.06%	-4.61%	-4.16%
1 Year Performance	-31.90%	1.28%	15.01%	4.58%

Veru Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VERU Veru	2.3833 of 5 stars	$2.54 +1.2%	$24.50 +864.6%	-31.9%	$43.31M	$16.89M	N/A	230	Analyst Downgrade
LFCR Lifecore Biomedical	1.5567 of 5 stars	$4.25 +3.2%	$6.50 +52.9%	-40.1%	$155.96M	$128.87M	N/A	690	Positive News Upcoming Earnings
IMUX Immunic	3.0714 of 5 stars	$11.23 -1.7%	$47.25 +320.7%	-0.4%	$155.81M	N/A	N/A	70	Positive News
MENS Jyong Biotech	N/A	$2.08 +4.5%	N/A	-96.6%	$151.29M	N/A	N/A	31	Positive News Gap Up
NRXP NRx Pharmaceuticals	1.8376 of 5 stars	$3.49 +2.6%	$34.50 +888.5%	+1.4%	$147.21M	$3.39M	N/A	2

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VERU) was last updated on 9/27/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Veru (VERU) Competitors

VERU vs. LFCR, IMUX, MENS, NRXP, and UNCY

How does Veru compare to Lifecore Biomedical?

Summary

How does Veru compare to Immunic?

Summary

How does Veru compare to Jyong Biotech?

Summary

How does Veru compare to NRx Pharmaceuticals?

Summary

How does Veru compare to Unicycive Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERU vs. The Competition

Veru Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Veru (VERU) Competitors

VERU vs. LFCR, IMUX, MENS, NRXP, and UNCY

How does Veru compare to Lifecore Biomedical?

Do insiders and institutionals have more ownership in VERU or LFCR?

Is VERU or LFCR more profitable?

Do analysts recommend VERU or LFCR?

Does the media favor VERU or LFCR?

Which has more volatility and risk, VERU or LFCR?

Which has better earnings & valuation, VERU or LFCR?

Summary

How does Veru compare to Immunic?

Is IMUX or VERU more profitable?

Which has more risk & volatility, IMUX or VERU?

Which has better valuation & earnings, IMUX or VERU?

Does the media refer more to IMUX or VERU?

Do institutionals and insiders have more ownership in IMUX or VERU?

Do analysts rate IMUX or VERU?

Summary

How does Veru compare to Jyong Biotech?

Is MENS or VERU more profitable?

Which has stronger valuation & earnings, MENS or VERU?

Do institutionals & insiders believe in MENS or VERU?

Does the media favor MENS or VERU?

Do analysts rate MENS or VERU?

Which has more risk and volatility, MENS or VERU?

Summary

How does Veru compare to NRx Pharmaceuticals?

Which has more volatility and risk, VERU or NRXP?

Do analysts rate VERU or NRXP?

Is VERU or NRXP more profitable?

Which has preferable valuation and earnings, VERU or NRXP?

Does the media refer more to VERU or NRXP?

Do insiders & institutionals have more ownership in VERU or NRXP?

Summary

How does Veru compare to Unicycive Therapeutics?

Do insiders and institutionals hold more shares of VERU or UNCY?

Does the media prefer VERU or UNCY?

Which has better earnings and valuation, VERU or UNCY?

Do analysts prefer VERU or UNCY?

Is VERU or UNCY more profitable?

Which has more risk and volatility, VERU or UNCY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VERU vs. The Competition

Veru Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools